Terms: = Breast cancer AND SUZ12, CHET9, 23512, ENSG00000178691, Q15022, KIAA0160, JJAZ1 AND Diagnosis
3 results:
1. Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments.
Mieczkowska IK; Pantelaiou-Prokaki G; Prokakis E; Schmidt GE; Müller-Kirschbaum LC; Werner M; Sen M; Velychko T; Jannasch K; Dullin C; Napp J; Pantel K; Wikman H; Wiese M; Kramm CM; Alves F; Wegwitz F
Cell Death Dis; 2021 Nov; 12(12):1118. PubMed ID: 34845197
[TBL] [Abstract] [Full Text] [Related]
2. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
Beltjens F; Molly D; Bertaut A; Richard C; Desmoulins I; Loustalot C; Charon-Barra C; Courcet E; Bergeron A; Ladoire S; Jankowski C; Boidot R; Arnould L
Int J Cancer; 2021 Jul; 149(1):200-213. PubMed ID: 33634878
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation.
Selenica P; Conlon N; Gonzalez C; Frosina D; Jungbluth AA; Beets-Tan RGH; Rao MK; Zhang Y; Benayed R; Ladanyi M; Solit DB; Chiang S; Hyman DM; Hensley ML; Soslow RA; Weigelt B; Murali R
Am J Surg Pathol; 2021 Jan; 45(1):77-92. PubMed ID: 32889887
[TBL] [Abstract] [Full Text] [Related]
